{"title":"家族性低脂蛋白血症(FHBL)的独特病例","authors":"Daniel Soffer MD, Sohil Golwala MD","doi":"10.1016/j.jacl.2024.04.073","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Synopsis</h3><p>RG is a 43-year-old male with fatty liver disease, found to have low total and low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) levels.</p></div><div><h3>Objective/Purpose</h3><p>To review a clinical scenario where making the proper lipid/lipoprotein diagnosis explains the background common coincident condition (fatty liver).</p></div><div><h3>Methods</h3><p>Patient was seen in the office at Lipid Clinic at Penn for further evaluation.</p></div><div><h3>Results</h3><p>RG is a 43-year-old obese male is referred to lipid clinic for further evaluation after initial presentation of abnormal liver function tests and very low cholesterol. There is a longstanding >15 years history of abnormal liver function tests and radiographic suspicion of fatty liver disease and liver biopsy showing moderate macrovesicular steatosis with mild steatohepatitis.</p><p>Genetic testing confirmed a pathogenic variant in the APOB gene associated with a diagnosis of autosomal dominant familial hypobetalipoproteinemia (FHBL). FHBL is primarily caused by pathogenic changes in the APOB gene but it has also been associated with pathogenic variants in other genes, including ANGPTL3 and PCSK9.</p><p>This condition is associated with a low risk of developing atherosclerotic cardiovascular disease (ASCVD) and high risk for development of fatty liver disease.</p><p>RG has coronary artery calcium score (CACS) = 0. He was counseled on natural history and inheritance pattern of this condition. There is no pharmacologic treatment required, but he was advised to supplement with fat-soluble vitamins and follow up with his primary team for ongoing care of liver disease.</p></div><div><h3>Conclusions</h3><p>Familial hypobetalipoproteinemia (FHBL) is a monogenic lipid disorder, characterized by low total and LDL-C. This condition is due to mutations in APOB gene that disrupts normal apoB protein synthesis. This condition is typically well-tolerated, but can be a cause of fatty liver disease and even cryptogenic cirrhosis. It is important to identify the correct cause of fatty liver disease since it may be reversible and because patients regularly report feeling accused by health professional when questioned about alcohol consumption or other lifestyle transgressions as a cause of their disease. Clarification of the diagnosis will enable proper lifestyle counseling and care.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"18 4","pages":"Pages e543-e544"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unique Case of Familial Hypobetalipoproteinemia (FHBL)\",\"authors\":\"Daniel Soffer MD, Sohil Golwala MD\",\"doi\":\"10.1016/j.jacl.2024.04.073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background/Synopsis</h3><p>RG is a 43-year-old male with fatty liver disease, found to have low total and low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) levels.</p></div><div><h3>Objective/Purpose</h3><p>To review a clinical scenario where making the proper lipid/lipoprotein diagnosis explains the background common coincident condition (fatty liver).</p></div><div><h3>Methods</h3><p>Patient was seen in the office at Lipid Clinic at Penn for further evaluation.</p></div><div><h3>Results</h3><p>RG is a 43-year-old obese male is referred to lipid clinic for further evaluation after initial presentation of abnormal liver function tests and very low cholesterol. There is a longstanding >15 years history of abnormal liver function tests and radiographic suspicion of fatty liver disease and liver biopsy showing moderate macrovesicular steatosis with mild steatohepatitis.</p><p>Genetic testing confirmed a pathogenic variant in the APOB gene associated with a diagnosis of autosomal dominant familial hypobetalipoproteinemia (FHBL). FHBL is primarily caused by pathogenic changes in the APOB gene but it has also been associated with pathogenic variants in other genes, including ANGPTL3 and PCSK9.</p><p>This condition is associated with a low risk of developing atherosclerotic cardiovascular disease (ASCVD) and high risk for development of fatty liver disease.</p><p>RG has coronary artery calcium score (CACS) = 0. He was counseled on natural history and inheritance pattern of this condition. There is no pharmacologic treatment required, but he was advised to supplement with fat-soluble vitamins and follow up with his primary team for ongoing care of liver disease.</p></div><div><h3>Conclusions</h3><p>Familial hypobetalipoproteinemia (FHBL) is a monogenic lipid disorder, characterized by low total and LDL-C. This condition is due to mutations in APOB gene that disrupts normal apoB protein synthesis. This condition is typically well-tolerated, but can be a cause of fatty liver disease and even cryptogenic cirrhosis. It is important to identify the correct cause of fatty liver disease since it may be reversible and because patients regularly report feeling accused by health professional when questioned about alcohol consumption or other lifestyle transgressions as a cause of their disease. Clarification of the diagnosis will enable proper lifestyle counseling and care.</p></div>\",\"PeriodicalId\":15392,\"journal\":{\"name\":\"Journal of clinical lipidology\",\"volume\":\"18 4\",\"pages\":\"Pages e543-e544\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical lipidology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S193328742400120X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S193328742400120X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Unique Case of Familial Hypobetalipoproteinemia (FHBL)
Background/Synopsis
RG is a 43-year-old male with fatty liver disease, found to have low total and low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) levels.
Objective/Purpose
To review a clinical scenario where making the proper lipid/lipoprotein diagnosis explains the background common coincident condition (fatty liver).
Methods
Patient was seen in the office at Lipid Clinic at Penn for further evaluation.
Results
RG is a 43-year-old obese male is referred to lipid clinic for further evaluation after initial presentation of abnormal liver function tests and very low cholesterol. There is a longstanding >15 years history of abnormal liver function tests and radiographic suspicion of fatty liver disease and liver biopsy showing moderate macrovesicular steatosis with mild steatohepatitis.
Genetic testing confirmed a pathogenic variant in the APOB gene associated with a diagnosis of autosomal dominant familial hypobetalipoproteinemia (FHBL). FHBL is primarily caused by pathogenic changes in the APOB gene but it has also been associated with pathogenic variants in other genes, including ANGPTL3 and PCSK9.
This condition is associated with a low risk of developing atherosclerotic cardiovascular disease (ASCVD) and high risk for development of fatty liver disease.
RG has coronary artery calcium score (CACS) = 0. He was counseled on natural history and inheritance pattern of this condition. There is no pharmacologic treatment required, but he was advised to supplement with fat-soluble vitamins and follow up with his primary team for ongoing care of liver disease.
Conclusions
Familial hypobetalipoproteinemia (FHBL) is a monogenic lipid disorder, characterized by low total and LDL-C. This condition is due to mutations in APOB gene that disrupts normal apoB protein synthesis. This condition is typically well-tolerated, but can be a cause of fatty liver disease and even cryptogenic cirrhosis. It is important to identify the correct cause of fatty liver disease since it may be reversible and because patients regularly report feeling accused by health professional when questioned about alcohol consumption or other lifestyle transgressions as a cause of their disease. Clarification of the diagnosis will enable proper lifestyle counseling and care.
期刊介绍:
Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.